Skip to main content
OpenTrials

Clinical trial condition

Invasive Breast Carcinoma

Explore clinical trials studying Invasive Breast Carcinoma. Study availability and eligibility vary by location and protocol.

91 public trials 20 recruiting studies
Refine in advanced search Browse all conditions

Invasive Breast Carcinoma trial results

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037

Conditions
Adenocarcinoma, Breast Carcinoma In Situ, Breast Ductal Carcinoma in Situ, +11 more
Locations
  • Northeast Alabama Regional Medical Center Anniston, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1568 locations
View Trial Details
Active, not recruiting

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

NCT01266642

Conditions
Adenocarcinoma, Breast Carcinoma In Situ, Breast Diseases, +19 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UF Cancer Center at Orlando Health Orlando, Florida, United States
  • MD Anderson in The Woodlands Conroe, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, not recruiting

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062

Conditions
Breast Diseases, Breast Neoplasms, Invasive Breast Carcinoma, +8 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 14 locations
View Trial Details
Active, not recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +16 more
Locations
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
View all 1024 locations
View Trial Details
Active, not recruiting

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NCT02912312

Conditions
Breast Diseases, Breast Neoplasms, Invasive Breast Carcinoma, +12 more
Locations
  • MD Anderson Cancer Center (Banner) Gilbert, Arizona, United States
  • Scripps- MD Anderson Cancer San Diego, California, United States
  • MD Anderson Cancer Center (Banner)- Northern Colorado Greeley, Colorado, United States
  • Baptist - MD Anderson Cancer Center Jacksonville, Florida, United States
View Trial Details
Active, not recruiting

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443

Conditions
Breast Diseases, Breast Neoplasms, Invasive Breast Carcinoma, +16 more
Locations
  • MD Anderson in The Woodlands Conroe, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson West Houston Houston, Texas, United States
  • MD Anderson League City League City, Texas, United States
View Trial Details
Active, not recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968

Conditions
Breast Adenocarcinoma, Breast Diseases, Breast Neoplasms, +17 more
Locations
  • St. Elizabeth Healthcare Edgewood, Kentucky, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University of Virginia Charlottesville, Virginia, United States
  • Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States
View Trial Details
Active, not recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596

Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, +4 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
View all 1176 locations
View Trial Details

Related conditions